PALATINE, Ill., Jan 08, 2018 -Acura Pharmaceuticals, Inc. (OTC QB: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that topline results from clinical study AP-LTX-301 (Study 301) for its LIMITx(TM) excess oral […]
Acura Pharmaceuticals, Inc (NASDAQ:ACUR)
Interview with Bob Jones, CEO […]
Fluoro Pharma Medical (OTCBB:FPMI)
Interview with Thijs Spoor, CEO and Chairman […]
CardioComm Solutions (TSX.V:EKG) CEO: Etienne Grima […]
StemCells, Inc (NASDAQ:STEM)
Interview with Martin McGlynn, Ceo […]
REVA Medical (ASX:RVA)
Interview with Bob Stockman, Ceo […]
IsoRay, Inc. (AMEX: ISR)
Interview with Dwight Babcock, Chairman and CEO […]
Revolutions Medical Corp (OTC BB: RMCP)
Interview with Ron Wheet, CEO […]
Cardiogenesis Corporation (OTC QB: CGCP)
Interview with Paul J. McCormick, Executive Chairman […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
